Background: In vitro fertilization for women with polycystic ovarian syndrome is an essential (PCOS). New methods to improve clinical outcomes are still needed. Objective: this research investigated the effectiveness of PPOS and compared it with the standard PCOS antagonist regimen. Materials and procedures: A total of 76 PCOS women eligible for aided therapy of reproductive technology were recruited in this RCT from February 2020 to May 2021 and put in random two groups (n=38/per group). Since the sixth day of the cycle, the PPOS group has received 20 mg/day orally of Dydrogesterone, while the control group received antagonist treatment. In addition to safety, our results were chemical and clinical pregnancy. Results: oocyte retrieval counts, oocyte metaphase II (MII) and MI have been comparable. There are also comparable numbers of fertilized oocytes and cleaved embryos without any statistical difference in the number of injected oocytes. Lower antagonistic gonadotropin dosage than the PPOS group (2957.8±301.9 vs 3197.4±545.9), with higher stimulation times respectively in the PPOS group than the antagonist. Similar findings across both main outcome groups (OHSS) with no instances of FPPOS and just one case (2.6 percent) of moderate OHSS antagonists. Similar findings also for secondary results (biochemical pregnancy rate , clinical pregnancy rate and miscarriage rate). Conclusion: the established In PCOS patients receiving IVF/ICSI therapy, PPOS is a safe and successful procedure.

Objectives:To determine the frequency of Helicobacter pylori (Hp) infection among primigravida and its relation to development of preeclampsia (PE). Patients and Methods:This cohort study included 146 primigravida evaluated prior to the 12th week gestational age, women who developed PE were categorized as PE group and a similar number of pregnant women free of hypertensive manifestations as control (No PE) group. All patients were evaluated for age and body mass index (BMI) and underwent Hp diagnosis workup including Urea breath test and Hp stool antigen testing.Results: Twenty-six women developed early and 47 developed late PE and 52 had mild, while 21 had severe PE. Development and severity of PE showed positive significant correlation with BMI. Sixty patients were Hp+; blood pressure measures at time of development of PE were significantly higher in Hp+ than in Hp-patients, irrespective of developing PE. Blood pressure measures and BMI showed positive significant correlation with Hp positivity. Statistical analysis defined high BMI as the significant independent predictor for development of PE. Conclusion:High BMI may underlie the development and severity of PE and is associated with Hp infection.

Background: Preterm delivery, defined as delivery before 37 weeks of pregnancy, is the leading global reason for neonatal mortality and morbidity. Preterm neonates have serious